Fzata's vision : Reduce health inequities by expanding patient access to therapeutic biologics. Our oral biologics for gastrointestinal (GI) disorders will:
improve patient accessibility to biologics with affordable, non-refrigerated, convenient oral capsules
improve patient compliance with no needles and no health-care administrated infusion
improve patient outcomes given the high safety profile for chronic use
The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) platform empowers orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases. BioPYM can target a wide variety of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, neurodegenerative diseases, and more. Utilizing BioPYM, we have developed a pipeline of oral biologics to treat GI-related disorders.
Fzata is proud to have been selected as "2017 Maryland Incubator Company of the Year, the Best Life Sciences Company". The award recognizes achievements by companies in Maryland business incubators.
We’re happy to hear from you. Contact us today to learn more about
the live yeast biotherapeutics BioPYM platform and benefits working with us.
Fzata, Inc. 1450 S. Rolling Rd, Room 4.097, Halethorpe, Maryland 21227 USA